(2-tert-Butylsulfanyl-ethyl)-dimethyl-amine | 153887-84-4

• 分子结构分类: 有机化合物 - 有机盐 - 有机金属盐
• 英文名称: (2-tert-Butylsulfanyl-ethyl)-dimethyl-amine
• 英文别名: 2-tert-butylsulfanyl-N,N-dimethylethanamine
• CAS: 153887-84-4
• 化学式: C₈H₁₉NS
• 分子量: 161.312
• InChiKey: GGNMUZPXZVTCHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  28.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tetra-(platinum(IV) trimethyl bromide) 、 (2-tert-Butylsulfanyl-ethyl)-dimethyl-amine 以 苯 为溶剂， 以53%的产率得到
  参考文献：
  名称：

  Synthesis and characterization of trimethylplatinum(IV) complexes with (2-dimethylaminoethyl)organochalcogenides (Me2NCH2CH2ER; E = S, Se, Te). X-ray crystal structure of [PtMe3Br(Me2NCH2CH2SC6H4Me-4)]

  摘要：

  Trimethylplatinum(IV) complexes of the type [PtMe3X(Me2NCH2CH2ER)] (X = Cl, Br, I; ER = SBu(t), SC6H4Me-4, SPh, SePh, TePh) have been prepared and characterized by elemental analysis and NMR (H-1 and C-13) spectral data. The structure of [PtMe3Br(Me2NCH2CH2SC6H4Me-4)] has been determined by single-crystal X-ray diffraction. The central platinum atom is coordinated by three fac-methyl groups and nitrogen, sulphur and bromine atoms. The five-membered chelate ring PtNCCS is non-planar.

  DOI：

  10.1016/s0277-5387(00)83057-0

文献信息

• ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  申请人：AbbVie Inc.

  公开号：US20170355769A1

  公开（公告）日：2017-12-14

  The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

  这项发明涉及B7同源物3蛋白（B7-H3）抗体和抗体药物结合物（ADCs），包括使用所述抗体和ADCs的组合物和方法。
• Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues
  申请人：Hodgetts J. Kevin

  公开号：US20070191363A1

  公开（公告）日：2007-08-16

  Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues are provided, of the formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了具有以下式子的杂原烷基取代的联苯-4-羧酸芳基酰胺类似物：其中变量如本文所述。这些化合物是配体，可用于体内或体外调节特定受体活性，并在治疗与人类、家畜伴侣动物和牲畜中的病理受体激活相关的疾病方面特别有用。还提供了用于治疗这些疾病的制药组合物和方法，以及用于受体定位研究的这些配体的方法。
• Inhibitors of Histone Deacetylase
  申请人：Moradei Oscar

  公开号：US20080132503A1

  公开（公告）日：2008-06-05

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制组蛋白去乙酰化酶。本发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了治疗细胞增殖性疾病和病症的组合物和方法。
• CHIRAL CONTROL
  申请人：WAVE LIFE SCIENCES PTE. LTD.

  公开号：US20150211006A1

  公开（公告）日：2015-07-30

  The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.

  本发明涉及手性控制的寡核苷酸、手性控制的寡核苷酸组合物以及其制备和使用方法。本发明特别涵盖了鉴定以前制备手性寡核苷酸方法中某些问题的来源，包括禁止制备完全手性控制的组合物，特别是包含多种寡核苷酸类型的组合物。在某些实施例中，本发明提供了手性控制的寡核苷酸组合物。在某些实施例中，本发明提供了制备手性控制的寡核苷酸和手性控制的寡核苷酸组合物的方法。
• Aromatic ionizable cationic lipid
  申请人：Arcturus Therapeutics, Inc.

  公开号：US10233148B2

  公开（公告）日：2019-03-19

  What is described is a compound of formula I wherein X is an alkylene or an alkenylene; Y is a monocyclic, bicyclic, or tricyclic arene or heteroarene; Z is S or O; L is a linear or branched alkylene of 1 to 6 carbons; R1 is a branched alkyl or alkenyl of 1 to 25 carbons; R2 is a alkyl or alkenyl of 1 to 20 carbons; R3 and R4 are independently a linear or branched alkyl of 1 to 6 carbons; n is 0 to 6; and m, p, q, and r are independently 1-18; or a pharmaceutically acceptable salt thereof.

  所述的是式 I 的化合物 式中 X 是亚烷基或烯基； Y 是单环、双环或三环芳烃或杂芳烃； Z 是 S 或 O； L 是 1 至 6 个碳原子的直链或支链烯烃； R1 是碳原子数为 1 至 25 的支链烷基或烯基； R2 是碳原子数为 1 至 20 的烷基或烯基； R3 和 R4 独立地是 1 至 6 个碳原子的直链或支链烷基； n 为 0 至 6；以及 m、p、q 和 r 独立地为 1-18； 或其药学上可接受的盐。